Redefining Injectables.
One Layer at a Time.

8 April, 2026

Notice of annual general meeting in Nanexa AB (publ)

The shareholders in Nanexa AB (publ),reg.no 556833–0285 (the ”Company”) are hereby given notice that the annual general meeting will be held on Tuesday 12 May 2026, at. 3:00 pm, at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden.

2 April, 2026

Nanexa announces exercise of warrants

Nanexa AB (publ) (“Nanexa” or the “Company”) today announces the exercise of warrants issued in connection with the Company’s directed issue of units, which was resolved upon by the Board of Directors on 24 January 2025. The directed issue consisted of units in two tranches, of which the first tranche was issued pursuant to the authorization from the Annual General Meeting held on 15 May 2024, and the second tranche was approved by the Extraordinary General Meeting on 13 February 2025. In connection with the directed issue, the Company also entered into loan agreements, whereby additional warrants were issued to the lenders as part of the overall financing solution (jointly the “Warrants”). All Warrants across the various tranches have now been exercised. In total, 27,878,788 Warrants have been exercised for the subscription of 27,878,788 new shares in the Company at a subscription price of SEK 2 per share. Through the exercise of the Warrants, Nanexa receives approximately SEK 55.7 million in total before transaction costs.

26 March, 2026

Nanexa publishes annual report for 2025

Download attachment

19 February, 2026

Nanexa publishes year-end report and Q4 report 2025

Download attachment